Products

Online Inquiry

Name

Email *

Phone *

Company/Institution

Country or Region

Quantity

Services & Products Interested *

Project Description

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Fasudil HCl (HA-1077)

inquiry

Cat No.

CEI-0839

Description

Fasudil is a potent inhibitor of ROCK-II, PKA, PKG, PKC, and MLCK with Ki of 0.33 μM, 1.6 μM, 1.6 μM, 3.3 μM and 36 μM, respectively.

Alias

AT-877

CAS No.

105628-07-7

Molecular Weight

327.83

Storage

2 years -20 centigrade Powder; 2 weeks 4 centigrade in DMSO; 6 months -80 centigrade in DMSO.

Synonyms

AT-877

Targets

ROCK-II, PKA, PKG, PKC, MLCK

IC50

0.33 μM (Ki); 1.6 μM (Ki); 1.6 μM (Ki); 3.3 μM (Ki); 36 μM (Ki)

Molecular Formula

C14H17N3O2S.HCl

Chemical Name

5-(1,4-diazepan-1-ylsulfonyl)isoquinoline hydrochloride

Solubility

DMSO 5 mg/mL; Water 66 mg/mL; Ethanol <1 mg/mL

In vitro

Fasudil is a class of calcium antagonists. Fasudil produces a competitive inhibition of the Ca2+-induced contraction of the depolarized rabbit aorta. Fasudil is able to inhibit contractile responses to KCl, phenylephnne (PHE) and prostaglandin (PG) F2a.Fasudil also exhibits vasodilator actions by inhibition of 5-hydroxytryptamine, noradrenaline, histamine, angiotensin, and dopamine induced spiral strips contraction.Fasudil induces disorganization of actin stress fiber and cell migration inhibition.Fasudil inhibits hepatic stellate cells spreading, the formation of stress fibers, and expression of α-SMA with concomitant suppression of cell growth, but does not induce apoptosis. Fasudil suppresses the LPA-induced phosphorylation of ERK1/2, JNK and p38 MAPK.

In vivo

Intra-coronary injection of Fasudil to dogs (30 μg i.a.) produces an approximate 50% increase in CBF. Fasudil (0.01, 0.03, 0.1 and 0.3 mg/kg, bolus, i.v.) dose-dependently decreases MBP and increases HR, VBF, CBF, RBF, and FBF. A total dose of 1.0 ng/mL Fasudil increases cardiac output. The infusion of Fasudil i.v. produces a significant fall in MBP, left ventricular systolic pressure and total peripheral resistance with an increase in HR and cardiac output, but without significant changes in right atrial pressure, dP/dt or left ventricular minute work in dogs.Fasudil administration displays protectable effects on cardiovascular disease and reduces the activation of JNK and attenuates mitochondrial-nuclear translocation of AIF under ischemic injury.The oral administration of Fasudil (a dosage of 100 mg/kg/day) significantly reduces incidence and mean maximum clinical score of EAE in SJL/J mice immunized with PLP p139-151. Treatment of mice with Fasudil suppresses the proliferative response of splenocytes to the antigen. Oral administration of Fasudil decreases inflammation, demyelination, axonal loss and APP positivein spinal cord of Fasudil-treated mice.